Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Bahlis, N, Dimopoulos, MA, White, DJ et al. (14 more authors) (2018) Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Metadata

Authors/Creators:
  • Bahlis, N
  • Dimopoulos, MA
  • White, DJ
  • Benboubker, L
  • Cook, G ORCID logo https://orcid.org/0000-0003-0223-3652
  • Leiba, M
  • Ho, PJ
  • Kim, K
  • Takezako, N
  • Moreau, P
  • Krevvata, M
  • Chiu, C
  • Qin, X
  • Okonkwo, L
  • Trivedi, S
  • Qi, M
  • San-Miguel, JF
Copyright, Publisher and Additional Information: © 2018 by The American Society of Hematology. This is an author produced version of a conference abstract published in Blood. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 29 November 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 17 Feb 2020 11:35
Last Modified: 17 Feb 2020 11:52
Status: Published
Publisher: American Society of Hematology
Identification Number: https://doi.org/10.1182/blood-2018-99-112697
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)